Liid Pharmaceuticals, Inc.

Liid Pharmaceuticals, Inc. is dedicated to advancing healthcare through innovative biotechnology research. Specializing in the development of Antisense Oligonucleotides (ASOs), Liid Pharmaceuticals leverages its proprietary BROTHERS (BRO) technology to enhance efficacy and improve safety profiles by reducing off-target effects. Liid Pharmaceuticals believes that ASOs developed with BRO technology hold significant potential in treating a variety of serious and life-threatening human diseases.

Liid Pharmaceuticals is actively building a diverse pipeline focused on addressing unmet medical needs. This includes potential treatments for Gaucher disease (lysosomal storage diseases), MASH (metabolic dysfunction-associated steatotic liver disease, NASH), and heart failure. The primary address of Liid Pharmaceuticals, Inc. is 6-1 Kishibe-Shinmachi, #21001 Open Innovation Center, National Cerebral & Cardiovascular Center, Suita, Osaka, JP.

Liid Pharmaceuticals is also open to collaborations with academia, biotech companies, and pharmaceutical firms. We are preparing to complete more information about Liid Pharmaceuticals, Inc. with the support of the company’s management, to better showcase our capabilities and mission. We invite the manager of Liid Pharmaceuticals, Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance your commercial development.